NPT
QNCX icon

Nixon Peabody Trust’s Quince Therapeutics QNCX Stock Holding History

Nixon Peabody Trust’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13K Hold
56
– – ﹤0.01% 160
2025
Q4 		$37.3K Hold
56
– – ﹤0.01% 160
2025
Q3 		$18.1K Hold
56
– – ﹤0.01% 152
2025
Q2 		$18.4K Hold
56
– – ﹤0.01% 148
2025
Q1 		$14.8K Hold
56
– – ﹤0.01% 152
2024
Q4 		$20.8K Hold
56
– – ﹤0.01% 146
2024
Q3 		$8.64K Hold
56
– – ﹤0.01% 139
2024
Q2 		$8.35K Hold
56
– – ﹤0.01% 128
2024
Q1 		$11.8K Hold
56
– – ﹤0.01% 126
2023
Q4 		$11.7K Buy
+56
New +$11.2K ﹤0.01% 130

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nixon Peabody Trust's QNCX Position: Q1 2026 in Review

Nixon Peabody Trust held its Quince Therapeutics (QNCX) position steady in Q1 2026 at 56 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #160.

Nixon Peabody Trust first reported a position in QNCX in Q4 2023 and has held it in 10 quarters since. The position peaked at $37.3K in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Nixon Peabody Trust held 56 shares of Quince Therapeutics worth $1.13K as of Q1 2026.
  • Nixon Peabody Trust left its Quince Therapeutics share count unchanged in Q1 2026.
  • Quince Therapeutics made up ﹤0.01% of Nixon Peabody Trust's portfolio in Q1 2026, its #160 holding.
  • Nixon Peabody Trust first reported a position in Quince Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Nixon Peabody Trust's Quince Therapeutics position peaked at $37.3K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Nixon Peabody Trust's 13F filing for Q1 2026, filed 27 Apr 2026.